FDA-cleared profile

brAIn™ Shoulder Positioning

Avatar Medical

brAIn Shoulder Positioning assists shoulder surgeons with preoperative planning and visualization for primary total shoulder replacement by segmenting shoulder CT data and allowing interactive implant positioning; it is an information tool and does not make the final surgical decision.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
brAIn Shoulder Positioning assists shoulder surgeons with preoperative planning and visualization for primary total shoulder replacement by segmenting shoulder CT data and allowing interactive implant positioning; it is an information tool and does not make the final surgical decision.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Shoulder surgeons and other trained healthcare professionals involved in shoulder arthroplasty planning.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Hospital and clinic orthopedic preoperative planning workflows.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
Segments the scapula and humerus, presents interactive 3D anatomy, and supports user-selected glenoid and humeral implant positions with planning summaries.
FDA source Exact FDA submission Checked 2026-09-04
Required input
Patient shoulder CT DICOM series and user-provided patient or planning information.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
Segmented scapula and humerus, interactive 3D views, implant-position views, distalization and lateralization measurements, and a multimodal planning summary with text and screenshots.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
The labeled use is preoperative information for primary total shoulder replacement; clinician review and final planning are required, and the FDA material does not establish recommendations or predictions for other procedures or populations.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243292
FDA source Exact FDA submission Checked 2026-08-31
Modality
CT/CTA
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Shoulder/scapula/humerus
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-03-20
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The FDA material describes upload of shoulder CT DICOM data to a cloud web application and export or display of planning summaries and screenshots.
FDA source Exact FDA submission Checked 2026-09-04

This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Deployment and data flow
The FDA material describes a cloud-based web application; current hosting, access control, retention, security, uptime, and local configuration remain unverified.
FDA source Exact FDA submission Checked 2026-09-04

This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only Shoulder surgeons and other trained healthcare professionals involved in shoulder arthroplasty planning should operate or interpret the product; local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-04
Monitoring and change control
Monitor K243292 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: The labeled use is preoperative information for primary total shoulder replacement; clinician review and final planning are required, and the FDA material does not establish recommendations or predictions for other procedures or populations.
FDA source Exact FDA submission Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K243292 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA material describes a cloud-based web application; current hosting, access control, retention, security, uptime, and local configuration remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA material describes upload of shoulder CT DICOM data to a cloud web application and export or display of planning summaries and screenshots.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The labeled use is preoperative information for primary total shoulder replacement; clinician review and final planning are required, and the FDA material does not establish recommendations or predictions for other procedures or populations.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K243292 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K243292 FDA material reports nonclinical verification and validation with 508 labeled 3D DICOM series, including 335 training and 173 testing series, and acceptance criteria of Dice similarity coefficient at least 0.95 and landmark mean distance no more than 3 mm; observed DSC beyond the criterion is not promoted.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Labeled shoulder CT series

508 3D DICOM series

Total validation dataset in Shoulder CT series used for K243292 development and testing.

Tested version: brAIn Shoulder Positioning configuration described in K243292

Testing partition

173 3D DICOM series

Held-out testing partition in Shoulder CT series held out for software validation.

Tested version: brAIn Shoulder Positioning configuration described in K243292

Segmentation Dice acceptance criterion

0.95 Dice coefficient

Minimum accepted segmentation agreement in Scapula and humerus segmentation validation.

Tested version: brAIn Shoulder Positioning configuration described in K243292

Landmark mean-distance acceptance criterion

3 mm

Maximum accepted landmark mean distance in Shoulder landmark validation.

Tested version: brAIn Shoulder Positioning configuration described in K243292

K243292 FDA evidence package for brAIn™ Shoulder Positioning

FDA 510(k) nonclinical software verification and validation with separated training and testing data for segmentation, measurements, and landmarks. · 508 3D shoulder CT DICOM series with labels; 335 training series and 173 testing series.

exact submission · Tested version: brAIn Shoulder Positioning configuration described in K243292 · n=508 · Sponsor or vendor study

K243292

The FDA material reports passed acceptance criteria, but those thresholds are not an independent clinical effectiveness study.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
Public source Not applicable Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243292 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
10Source classes checked
0Reviewed PubMed leads
0Reviewed trial leads
0Unreviewed FDA recall leads

The discovery snapshot contains no PubMed or ClinicalTrials.gov candidates for K243292; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare